Trial Profile
A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory chronic graft versus host disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 22 Jun 2020 Status changed from active, no longer recruiting to completed.
- 15 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 06 Nov 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.